<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04023630</url>
  </required_header>
  <id_info>
    <org_study_id>SAHZJU CT013</org_study_id>
    <nct_id>NCT04023630</nct_id>
  </id_info>
  <brief_title>DUAL Antithrombotic Therapy in Patients With AF and ACS</brief_title>
  <official_title>An Open-label, Randomized, Controlled, Multicenter Study to Evaluate DUAL Antithrombotic Therapy With Rivaroxaban Plus Ticagrelor vs. Rivaroxaban Plus Clopidogrel in Patients With Atrial Fibrillation and Acute Coronary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to show inferiority of rivaroxaban plus ticagrelor when compared to
      rivaroxaban plus clopidogrel in terms of safety. Safety will be determined by comparing the
      rates of death or ischemic event-including myocardial infarction, definite or probable stent
      thrombosis, stroke, or urgent revascularization.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective of this study is to compare a Dual Antithrombotic Therapy (DAT) regimen of
      rivaroxaban plus ticagrelor with rivaroxaban plus clopidogrel in Patients With Non Valvular
      Atrial Fibrillation (NVAF) and Acute Coronary Syndrome. The study aims to show inferiority of
      rivaroxaban plus ticagrelor when compared to rivaroxaban plus clopidogrel in terms of safety.
      Safety will be determined by comparing the rates of death or ischemic event-including
      myocardial infarction, definite or probable stent thrombosis, stroke, or urgent
      revascularization.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The composite endpoints of death and ischemic events</measure>
    <time_frame>one year</time_frame>
    <description>The composite endpoints of death and ischemic events (stroke, myocardial infarction, stent thrombosis, urgent revascularization )</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinically significant bleeding</measure>
    <time_frame>one year</time_frame>
    <description>Clinically significant bleeding is a composite of Thrombolysis in Myocardial Infarction (TIMI) major bleeding, minor bleeding, and bleeding requiring medical attention (BRMA)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">4000</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Acute Coronary Syndromes</condition>
  <arm_group>
    <arm_group_label>rivaroxaban plus ticagrelor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rivaroxaban 15 mg (or 10 mg for subjects with moderate renal impairment) once daily plus ticagrelor 90 mg tablet twice daily for 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rivaroxaban plus clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>rivaroxaban 15 mg (or 10 mg for subjects with moderate renal impairment) once daily plus clopidogrel 75 mg tablet once daily for 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban 15 MG Oral Tablet</intervention_name>
    <description>One 15 mg tablet once daily for up to twelve months</description>
    <arm_group_label>rivaroxaban plus clopidogrel</arm_group_label>
    <arm_group_label>rivaroxaban plus ticagrelor</arm_group_label>
    <other_name>Xarelto</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel 75 Mg Oral Tablet</intervention_name>
    <description>One 75 mg tablet once daily for up to twelve months</description>
    <arm_group_label>rivaroxaban plus clopidogrel</arm_group_label>
    <other_name>P2Y12 antagonists</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor 90 MG Oral Tablet</intervention_name>
    <description>One 90 mg tablet twice daily for up to twelve months</description>
    <arm_group_label>rivaroxaban plus ticagrelor</arm_group_label>
    <other_name>P2Y12 antagonists</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adults with either active or a history of non-valvular atrial fibrillation or flutter
             with the planned or existing use of an oral anticoagulant for prophylaxis of
             thromboembolism. In addition, subjects must have had an acute coronary syndrome

          2. Planned use of antiplatelet agents for at least 12 months

          3. Males and Females â‰¥ 18 years of age

          4. Women of childbearing potential must have a negative serum or urine pregnancy test
             within 24 hours prior to the start of study drug

        Exclusion Criteria:

          1. Conditions other than atrial fibrillation that require chronic anticoagulation. (e.g.
             prosthetic mechanical heart valve)

          2. Severe renal insufficiency (serum creatinine &gt; 2.5 mg/dL or a calculated creatinine
             clearance &lt; 30 mL/min

          3. Patients with a history of intracranial hemorrhage

          4. Patients have had or will undergo Coronary arterial bypass graft (CABG) for their
             index acute coronary syndrome (ACS) event

          5. Patients with known ongoing bleeding and patients with known coagulopathies

          6. Any contraindications or allergies to rivaroxaban, or to intended P2Y12 antagonists

          7. Have a history of stroke or Transient Ischemic Attack (TIA)

          8. Have known significant liver disease or liver function test (LFT) abnormalities

          9. Have any severe condition that would limit life expectancy to less than 12 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun Jiang, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Second Affiliated Hospital Zhejiang University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jun Jiang, PhD</last_name>
    <phone>13588706891</phone>
    <email>hu888po@126.com</email>
  </overall_contact>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 16, 2019</study_first_submitted>
  <study_first_submitted_qc>July 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2019</study_first_posted>
  <last_update_submitted>July 16, 2019</last_update_submitted>
  <last_update_submitted_qc>July 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Second Affiliated Hospital, School of Medicine, Zhejiang University</investigator_affiliation>
    <investigator_full_name>Jian'an Wang,MD,PhD</investigator_full_name>
    <investigator_title>President of Second Affiliated Hospital, School of Medicine, Zhejiang University &amp; Chief of Cardiology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

